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INTRODUCTION  
 
 Numerous studies have been conducted on acute and chronic pancreatitis , but 
only few have focused on recurrent acute pancreatitis(RAP). Recurrent acute pancreatitis  
may be due to biliary disease, alcohol, metabolic factors (hypercalcemia, 
hypertriglyceridemia), drugs, trauma, sphincter of Oddi dysfunction, pancreas divisum 
and pancreatic carcinoma(1)  Evaluation fails to detect the cause in 10 – 30% of patients , 
and these patients are labelled as idiopathic recurrent acute (IAP) pancreatitis(IRAP). 
Further evaluation and therapy is important because more than 50% of untreated patients 
with RAP  experience recurrent episodes that can lead to chronic pancreatitis(2) 
Mutations in cationic trypsinogen gene (PRSS1) , SPINK1 gene ,cystic fibrosis 
transmembrane conductance regulator gene (CFTR) and Cathepsin B gene have been 
demonstrated in acute and chronic pancreatitis(3-6).  It is possible that genetic mutations 
may be the cause of pancreatitis in patients now labelled as Idiopathic Recurrent 
Pancreatitis. Few patients with gall stones or alcoholism develop RAP. It is therefore 
conceivable that genetic mutations enhance susceptibility to RAP in patients with other 
predisposing factors. RAP may be a complex disease process resulting from an interplay 
of genetic susceptibilities and environmental factors. 
A systematic study on etiology ,clinical features , response to therapy and 
outcome in patients with RAP has not been carried out in India. We need to get data on 
the following: 
 (a) What are the common etiological factors causing RAP? 
 (b) What percentage of patients have Idiopathic RAP (IRAP)? 
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 (c ) What percentage of patients initially diagnosed as RAP develop chronic  
  pancreatitis on follow up? 
 (d) Response to therapy-Medical, Endoscopic . 
 (e) Morbidity and mortality. 
 Therefore , the aim of the present study was: (a) to study the clinical profile, 
efficacy of medical / endoscopic therapy and outcome of patients with RAP.(b) assess the 
prevalence of genetic mutations in a subset of patients with RAP. 
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AIMS AND OBJECTIVES 
 
1. To study the clinical profile, efficacy of medical / endoscopic therapy  
 and outcome of recurrent acute pancreatitis. 
 
2. To assess the prevalence of genetic mutations in recurrent acute pancreatitis. 
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REVIEW OF LITERATURE 
 
DEFINITIONS: 
Acute Pancreatitis:  is  defined as an acute inflammatory disease of the pancreas 
presenting with abdominal pain and usually associated with elevated pancreatic  
enzymes in  blood or urine(7). 
 
Mild Acute pancreatitis: there is no multisystem failure and uncomplicated recovery. 
 
Severe Acute pancreatitis: there is early or late local or systemic complications 
(multisystem failure) associated with high morbidity & mortality(7). 
 
Recurrent Acute pancreatitis:  is defined as two or more attacks of pancreatitis 
associated with at least twice normal serum amylase levels (8). 
 
Chronic Pancreatitis: has been defined as a continuing inflammatory disease of the  
pancreas characterised by irreversible morphologic changes that typically causes pain  
and/or permanent loss of exocrine and/or endocrine function(7). 
 
INCIDENCE: 
 Wang et et al (9) from a China showed that of 1471 cases of acute  pancreatitis, 
only 157 cases (10.6%) were recurrent acute pancreatitis.Zhang et al (10) from Shanghai 
showed an incidence of  31.43% (77/245).The data from Europe by Gullo et al (11) 
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showed that out of the 1068 cases of acute pancreatitis ,288 (27%) had 
recurrence.Another study by Sanchez et al (12) in showed an incidence of 34.5%. 
ETIOLOGY: 
 Virtually any factor capable of causing an initial episode of acute pancreatitis  
has the potential to incite recurrent episodes (1). 
GALLSTONES : 
 Only 3 to 7 percent of patients with gallstones develop pancreatitis(13,14).  
Gender(risk greater in men.  and stone size(stone diameter < 5 mm(15,16) may be risk 
factors. Cholecystectomy and clearing the common bile duct of stones prevents 
recurrence, confirming the cause-and-effect relationship(13). The possible initiating event 
in gallstone pancreatitis may be  reflux of bile into the pancreatic duct due to transient 
obstruction of the ampulla during passage of gallstones or obstruction at the ampulla 
secondary to stone(s) or edema resulting from the passage of a stone (17).  Serum alanine 
aminotransferase (ALT) concentration was the most clinically useful parameter in 
predicting a gallstone etiology in a meta-analysis(18).  ALT concentration of 150 IU/L or 
more (approximately a threefold elevation) had a positive predictive value of 95 percent 
for the diagnosis of gallstone pancreatitis. 
BILIARY SLUDGE AND MICROLITHIASIS: 
 Biliary sludge is a viscous suspension in gallbladder bile that may contain small 
stones (<5 mm in diameter), cholesterol monohydrate crystals or calcium bilirubinate 
granules which is  formed by modification of hepatic bile by gallbladder mucosa(19-21).  
Sludge is typically found in patients with functional or mechanical bile stasis due to  
prolonged fast, total parenteral nutrition, distal bile duct obstruction, rapid weight loss, 
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pregnancy,bone marrow or solid organ transplantation and drugs (ceftriaxone ,  
cyclosporine and ocreotide.(22) Sensitivity of  USG abdomen  for  sludge is  60% while  
microscopic examination for cholesterol crystals has a sensitivity of  65-90% and EUS   
95%. (19) Two uncontrolled studies suggest that biliary sludge can lead to pancreatitis  as  
these patients benefit from intervention (21,23).  
 Dissolution of  microliths by UDCA , endoscopic sphincterotomy or  
cholecystectomy prevented further attacks of pancreatitis.  
ALCOHOL: 
 Approximately 10 percent of alcoholics develop attacks of acute pancreatitis  
even though the classic teaching is that alcohol causes chronic pancreatitis(24).  
Some have nonprogressive recurrent alcohol-induced acute pancreatitis.(25).  
Alcohol may act by inducing pancreatic acinar cells to synthesize the digestive 
and lysosomal enzymes responsible for acute pancreatitis or  sensitize the acini  to  
cholecystokinin.(26).The reason why only a small proportion of all alcoholics develop   
pancreatitis as well as the genetic and environmental influence in the development of   
pancreatitis in alcoholics is not clear. 
SPHINCTER OF ODDI DYSFUNCTION: 
Sphincter of Oddi is a 5-15 mm long fibromuscular sheath surrounding the 
terminal CBD ,pancreatic duct and common channel.(27) Frequency of SOD in IRAP is  
35%.(mean of 6 studies.) The terms papillary stenosis, sclerosing papillitis, biliary spasm,  
biliary dyskinesia, and postcholecystectomy syndrome have been used synonymously  
with sphincter of Oddi dysfunction (SOD). (28) . Two separate pathologic entities are  
described (1) Sphincter of Oddi stenosis (2) sphincter of Oddi dyskinesia  
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 SOD has been associated with two clinical syndromes: biliary pain without other  
apparent causes in the setting of  cholecystectomy (postcholecystectomy syndrome) and  
idiopathic recurrent pancreatitis and pancreatitis occurring after ERCP. (29,30). 
Gold standard  for diagnosis is sphincter of Oddi manometry (SOM). (31).   
SOD in the setting of IAPis treated by endoscopic biliary or both biliary and pancreatic  
sphincterotomy.(32) Efficacy  was 60-100% ,and complications were around 30 %.  
Recurrence rate of SOD was about 10-20%.(32)  
PANCREAS DIVISUM: 
 It is the most common congenital pancreatic anomaly, occurring in approximately 
7% of subjects in autopsy series (range 1 to 14 percent).It  arises from failure of  
fusion of the ventral and dorsal pancreatic ducts in the second month of gestation, 
causing 80-95% of pancreatic juice to flow via dorsal duct through the minor 
papilla .The classic pancreas divisum consists of a small ventral duct which drains  
through the major papilla and the larger dorsal duct which drains through the minor  
papilla. In incomplete pancreas divisum, seen in 15 % of cases of pancreas divisum, a  
tiny branch of the ventral duct communicates with the dorsal duct. (15 percent ) (33).In  
"reverse" divisum ,there is an isolated small segment of dorsal pancreas  when the  
accessory duct of Santorini does not connect with the genu of  the main pancreatic duct.  
Santorinicele refers to a cystic dilatation of the dorsal pancreatic duct in pancreas  
divsum as it enters the duodenal wall(34,35).  Although controversial, most believe that  
pancreas divisum is a cause of RAP occurring in about 20% of the patients(36)  
Diagnosis is  by ERCP / MRCP (37).  Secretin improves ductal visualization during  
MRCP. Treatment  is directed towards relieving outflow obstructionat the level of minor  
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papilla.Minor papillary sphincterotomy leads to symptom relief in 70-90%. 
DRUGS : 
 Clear evidence of a definite association with pancreatitis exists for 
didanosine,sodium valproate , aminosalicylates, estrogen, calcium, anticholinesterases 
and sodium stibogluconate. An association likely but not definitely proven is for thiazide 
diuretics, pentamidine, ACE inhibitors, asparaginase, vinca alkaloids, some nonsteroidal 
anti-inflammatory drugs and clozapine. Pancreatitis is possibly caused by azathioprine,  
furosemide , tetracycline, metronidazole, isoniazid, rifampicin , sulphonamides,  
cyclosporin and some antineoplastic drugs.(38)  The pathogenesis may be due to an  
idiosyncratic response in ( 6-mercaptopurine, aminosalicylates, sulfonamides) or to a  
direct toxic effect (eg, diuretics, sulfonamides)and angioedema of the gland with  
angiotensin converting enzyme inhibitors .  
HYPERTRIGLYCERIDEMIA: 
 This accounts for 1.3 to 3.8 percent of acute pancreatitis(39).   Serum triglyceride  
concentrations above 1000 mg/dL  can  precipitate recurrent attacks of acute 
pancreatitis(40).  Another study by Fortson et al reported the cut off of 500mg/dL(39). The  
pathogenesis of inflammation in this setting is unclear.This  has been best studied in  
children with inherited disorders of lipoprotein metabolism associated with severe  
hypertriglyceridemia .The acquired causes of hypertriglyceridemia are alcohol abuse ,  
obesity, diabetes mellitus, hypothyroidism, pregnancy, estrogen or tamoxifen therapy,  
glucocorticoid excess, nephrotic syndrome, and beta blockers (40). The serum amylase  
may not be substantially elevated due to unclear reasons.  
HYPERCALCEMIA:  
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 Hypercalcemia of any cause can lead to recurrent acute pancreatitis.(41). The 
proposed mechanisms is  calcium activation of trypsinogen within the pancreatic 
parenchyma(42).   Even though, hyperparathyroidism is associated with pancreatitis, the 
actual incidence of recurrent acute pancreatitis in patients with hyperparathyroidism is 
low (43)  
INFECTION: 
 Infections associated with acute pancreatitis are (44,45) 
Viruses — Mumps, Coxsackievirus, hepatitis A,B, and C , CMV, varicella-zoster, HIV 
Bacteria — Campylobacter jejuni,Mycobacterium tuberculosis and avium complex,  
Mycoplasma, Legionella, Leptospira, Salmonella  
Fungi — Aspergillus  
Parasites — Ascaris, Toxoplasma, Cryptosporidium, Microsporidium,Clonorchis .  
BILIARY ASCARIASIS: 
 Commonly reported from endemic regions of  Far East, India, Latin America, and 
Middle East. Common disease presentations include biliary colic, obstructive jaundice,  
acalculous cholecystitis, choledocholithiasis, pancreatitis, and cholangitis. (46), 
In a study by Khuroo et al(46), Ascariasis was the etiologic factor in 36.7% cases of   
pancreatitis.ERCP is used  for diagnosis and extraction of worms . 90% patients recover  
with endoscopic treatment followed by anthelminthic therapy. Surgery is reserved for  
trapped worms in the ducts not removable by endoscopy. 
TRAUMA: 
 Blunt or penetrating trauma can damage the pancreas (47). Healing of pancreatic 
ductal injuries leads to scarring and stricture of main pancreatic duct and pancreatitis. 
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VASCULAR DISEASES: 
 Pancreatic ischemia from vasculitsis (systemic lupus erythematosus and 
polyarteritis nodosa) (48) is a rare cause of  significant recurrent pancreatitis. Most have 
mild attacks of pancreatitis secondary to ischemia.  
TUMORS: 
 5-7 %  of  patients with  pancreatobiliary  tumors  present with RAP (27).  
Pancreatic cancer should be suspected in any patient older than 40 or 45 years who has 
unexplained pancreatitis.with a prolonged or recurrent course.(49) The tumors of the major 
duodenal papilla (adenoma and carcinoma and rarely islet cell tumors ,lymphoma , 
neurofibroma, or metastatic tumors ) can present with recurrent acute pancreatitis (50). 
 Cystic pancreatic tumors (27) such as serous and mucinous cystadenomas and 
Intraductal papillary mucinous neoplasms (IPMN) can present with RAP. The 
pathognomonic duodenoscopic findings are a patulous papilla and mucin extrusion from 
the papillary orifice.They have an obvious malignant potential and early recognition and 
resection are the cornerstone of treatment.Ampullary tumors,the most common being 
adenomas are premalignant and have a more favourable prognosis with 
pancreatoduodenectomy. (49) 
 Endoscopic techniques can be used for small lesions which are benign or with 
carcinoma in situ, especially with ampullary adenomas.This can be achieved by snare 
ampullectomy or piecemeal snare resection. Tumor ablation can be done by NDYag 
laser,multipolar cautery,or argon plasma coagulation. Levy et al recommend an initial 
follow up after 3 months and yearly thereafter. 
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ANOMALOUS UNION  OF PANCREATICOBILIARY DUCT.(AUPBD). 
 This is defined as anomalous junction of the bile duct and pancreatic duct at an  
abnormally proximal site and long (>15mm )common pancreatobiliary channel.(27) The  
junction is located outside the duodenal musculature and not controlled by the sphincter  
of Oddi leading to regurgitation of pancreatic juice into biliary tract and vice versa  
causing recurrent acute pancreatitis.(51) .The stasis  of pancreatic secretion in the  
common channel as well as concurrent SOD can also cause pancreatitis. AUPBD is  
frequently associated with choledochal cyst and is more common in East Asia.(52) 
The diagnosis is made on ERCP ; the pancreatic duct and bile duct fills simultaneously  
with contrast and connect with an  obviously long channel(>15mm in adult) (53,54)  When  
the amylase in the aspirated bile is high,the presence of AUPBD is strongly suggested. 
(55) Endoscopic sphincterotomy may be effective in preventing recurrent attacks.(55) 
AUPBD is a premalignant condition that can progress to gall bladder or  
cholangiocarcinoma .Prophylactic cholecystectomy is recommended in patients with  
AUPBD with no biliary dilatation.(56).  But in patients with AUPBD and choledochal  
cyst, extensive resection of extrahepaic bile duct along with cyst and biliary diversion  
procedure is recommended. 
 
CHOLEDOCHOCELE: 
 This is a prolapse or herniation of the intramural segment of the distal CBD into 
the duodenal lumen. Todani  classified it as Type III choledochal cyst. (57). Recurrent  
pancreatitis occurrs in 12-25 % of patients.(58).  Choledochocele  may cause intermittent  
obstruction of the pancreatic duct when it become distended with bile.Reflux of bile into  
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the pancreas can activate pancreatic enzymes leading to recurrent episodes of  
pancreatitis.(58,59). Diagnosis is by ERCP.(60).  Endoscopically, the papilla has a bulging  
appearance and feels soft (Pillow sign) when pressure is applied with the catheter tip.(61)   
Treament includes endoscopic  sphincterotomy and unroofing of the choledohocele with  
a papillotome.(62). Surgical excision is done for a large choledochocoele . 
ANNULAR PANCREAS: 
 This is a congenital anomaly that manifests as a band of pancreatic tissue partially 
or completely encircling the duodenum ,usually at the level of or just proximal to the  
major duodenal papilla.(63).  Symptoms begin in childhood with  duodenal  
obstruction.Childhood disease is associated with congenital anomalies such as Downs  
syndrome, cardiac defects tracheoesophageal fistula,Meckels diverticulum and  
imperforate anus.(64) Adults may present with recurrent acute pancreatitis, chronic  
pancreatitis,peptic ulcer or biliary obstruction.(2) Pancreatitis may be due to stasis of  
pancreatic juice.(63). Pancreas divisum is present in one third of  patients . (65)  
Diagnosis is by ERCP.(63).Gastrojejunostomy may be required to bypass the  
obstructed bowel segment.(66)  Division of annulus ,once the procedure of choice ,is no  
longer performed because of the risk of pancreatitis and pancreatic fistula. 
 
GENETIC MUTATIONS: 
TRYPSIN AND ACUTE PANCREATITIS 
 Acute pancreatitis is caused by unregulated trypsin activity within the pancreatic 
acinar cell or pancreatic duct that leads to zymogen activation, pancreatic autodigestion, 
and pancreatic inflammation ie pancreatitis.(67)  
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 Trypsin:-  is a major pancreatic serine protease with two globular protein domains 
connected by a single side chain on the surface opposite the active site.Trypsinogen  
becomes trypsin with cleavage of a short exposed peptide chain called trypsinogen  
activation peptide by the action of enterokinase or by a second trypsin molecule. 
The trypsin contains a calcium binding pocket near the side chain connecting the two  
globular domains. This side chain (autolysis loop) contains an arginine residue at amino  
acid position 117 (coded for by codon 122 — ie   R122), which is a target for attack by  
other trypsin enzymes.Enzymatic cleavage of the side chain at R122 by the second  
trypsin leads to rapid destruction of  the first trypsin molecule (autolysis). As the  
concentration of soluble calcium rises, calcium enters the calcium binding pocket and  
limits exposure of R122 to enzymatic attack by another trypsin.(68) and protects  
trypsin from autolysis.  
 Trypsin is susceptible to rapid autolysis within the acinar cell where calcium  
levels are low, protected from autolysis after active secretion into the pancreatic duct and   
duodenum where calcium levels are high, and then undergoes autolysis in the  distal small  
intestine after calcium is absorbed in the distal duodenum and jejunum.  
Protective mechanisms against acute pancreatitis:   
 Intracellular protective mechanisms include synthesis of trypsin as an inactive 
zymogen (trypsinogen), zymogen compartmentalisation and packaging, synthesis of a 
specific trypsin inhibitor ( PSTI or SPINK1), R122 dependent trypsinogen / trypsin 
autolysis, control of intra-acinar cell calcium levels (to facilitate autolysis), and lysosome 
dependent pathways of zymogen/activated digestive enzyme elimination.(69).  Once the 
zymogens are secreted into a calcium rich juice (eliminates the autolysis protective 
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mechanism) the pancreas is dependent on SPINK1 (inhibit  prematurely activated 
trypsinogen), and rapid flushing of the pancreatic duct by fluid from the duct  
cells to protect against pancreatitis.Duct flushing is a cystic fibrosis transmembrane  
conductance regulator (CFTR) dependent protective mechanism. Disruption of any of  
these protective mechanisms increases susceptibility to acute pancreatitis and predisposes  
to chronic pancreatitis. The combined effect of environmental and genetic factors in  
increasing the risk of  recurrent acute pancreatitis is given in figure below. 
Relationship between risk factors and genetics in developing recurrent acute  
Pancreatitis(69):- 
  
 It is possible that environmental triggering factors leads to acute pancreatitis in a 
susceptible individual with underlying genetic predisposition. (69) 
Cationic Trypsinogen mutations: 
 Most cases of hereditary pancreatitis are associated with mutations in the cationic  
trypsinogen gene (PRSS1)(4) .  The R122H and N29I mutations which are gain  
of function mutations interferes with autolysis and/or cause premature trypsinogen  
activation.(70) . Between 60% and 80% of individuals who inherit the mutation  
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usually develop pancreatitis.(69) Approximately half of individuals with acute  
pancreatitis will develop chronic pancreatitis, and up to 40% of individuals with chronic  
pancreatitis will develop pancreatic cancer. A patient with a gain of function PRSS1 gene  
will have at least one other family member with recurrent acute or chronic pancreatitis.(71)  
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SPINK1 mutations: 
 
 
 
 
 SPINK1 acts as the first line of defense against prematurely activated trypsinogen 
in acinar cells.If there is ineffective inhibition by mutant SPINK1 , free trypsin activity  
increases and initiates activation of other zymogens.SPINK1 N34S allele is associated  
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with acute and chronic pancreatitis.(72).The association is weak, with <1%  of  
mutation carriers developing  pancreatitis sometime during their lifetime.(69)  The  
SPINK1 N34S allele acts as either a modifier gene or a susceptibility factor for a  
polygenic complex  trait. (73). Felderbauer and colleagues identified an  interaction  
between SPINK1 and mutations in the calcium sensing receptor gene.These mutations  
cause familial hypocalciuric hypercalcaemia, characterised by benign elevation in plasma  
calcium levels.(74) Patients with both HFF and the SPINK1 N34S allele mutations have  
multiple episodes of recurrent abdominal pain, pancreatitis, and eventually developed  
chronic pancreatitis.The SPINK1 N34S allele modifies the HFF phenotype to cause  
recurrent acute and chronic pancreatitis.(75) 
 
CFTR gene mutations 
 The CFTR functions as a chloride channel in the apical membrane of most 
secretory epithelium including pancreatic ductal epithelial cells.With CFTR gene 
mutations , ductal water flow is reduced owing to defective anion secretion. Protein 
concentration in the duct rises which causes precipitation of protein and plugging of 
ductal lumina.(69). 
 CFTR gene is located on the long arm of chromosome 7 (7q31). The most  
common mutation causing cystic fibrosis is a 3- base pair deletion causing loss of phenyl 
alanine 508( Delta F 508). When both alleles of  CFTR gene are affected by severe  
mutations ,classic cystic fibrosis results with pancreatic insufficiency.Compound  
heterozygosity of CFTR gene with one severely affected and one moderately affected  
allele has been shown to be a cause of recurrent pancreatitis. In these patients , there are  
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no  clinical signs of  classic cystic fibrosis , no nasal polyps and sweat chloride is within  
the normal range.(69) 
 CFTR may be part of  a complex  in which heterozygous CFTR and heterozygous  
SPINK1 mutations cause recurrent acute pancreatitis when occurring  
together. CFTR  variants may also increase susceptibility to  environmental factors  
such  as alcohol.(69)       
 
Cathepsin B (CTSB) 
 Cathepsin B is a lysosomal cysteine proteinase , involved in the initial activation 
of trypsinogen .CTSB is abundantly secreted from the human exocrine pancreas and  
contained in the pancreatic secretory zymogen granules rather than in the lysosomes  
CTSB can activate trypsinogen in vitro. In fact 90% of the activation of trypsinogen  
during experimental pancreatitis is accounted for by CTSB and it disappears when the  
ctsb- gene is deleted.(76) 
 A recent study by Madhurkar et al compared 2 separate cohort of  patients with  
tropical pancreatitis totalling 306 patients (about 50% had SPINK1 mutations) with  
330 controls. C76G polymorphism that results in leucine to valine mutation at aminoacid  
26 was twice as common in patients with tropical pancreatitis. CTSB mutation also  
doubled the risk for tropical pancreatitis irrespective of whether patients were positive or  
negative for N34S mutation in SPINK1.(77) 
 Recurrent acute pancreatitis has rarely been described in patients with 
suprapapillary duodenal diverticulum,brunneromas and hydatid cyst of the head of 
pancreas.   
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PATHOGENESIS: 
 Though a number of animal models have been developed ,none is strictly 
compared to the human condition. 
SAPE (sentinel acute pancreatitis event) hypothesis model (78).:- 
 
 Precipitants like alcohol ,genetic and other environmental factors reduces the 
threshold for acute pancreatitis and the first or sentinel acute pancreatitis event initiates 
the inflammatory process with infiltration of the gland by inflammatory cells. 
In late acute pancreatitis ,anti-inflammatory cells limits inflammation and healing starts 
with activation of stellate cells and consequent fibrosis. Recurrent episodes perpetuates 
these events and lead to acinar cellloss and sclerosis leading to chronicity. 
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EARLY ACUTE CHANGES: 
Intraacinar activation of proteolytic enzymes:  
 The intrapancreatic release of  trypsin leads to further activation of  more trypsin, 
and other enzymes like phospholipase, chymotrypsin, elastase, activation of complement,  
kallikrein-kinin, coagulation, and fibrinolysis. The active enzymes leads to pancreatic  
autodigestion, and spread of  destruction  into the peripancreatic tissue.(79) 
Microcirculatory injury:  
 The enzymes damage the vascular endothelium , interstitium and  the acinar 
cells(79) leading to vasoconstriction, capillary stasis, decreased oxygen  
saturation, and progressive ischemia, These changes lead to increased vascular  
permeability and swelling of the gland (edematous or interstitial pancreatitis) (80). 
Reperfusion of damaged tissues leads to the  release of free radicals and inflammatory  
cytokines into the circulation, causing further injury.(80) 
 Leukocyte chemoattraction, release of cytokines, and oxidative stress.  There is 
glandular invasion by macrophages and polymorphonuclear leukocytes in early stages (81) 
with subsequent release of proinflammatory cytokines (TNF, IL-1, 6, and 8), arachidonic 
acid metabolites (PG , PAF, and LT ), proteolytic and lipolytic enzymes, and reactive 
oxygen metabolites .These substances also interact with the pancreatic microcirculation 
to increase vascular permeability and induce thrombosis and hemorrhage, leading to 
pancreatic necrosis. 
Systemic Response: 
 Some patients develop systemic inflammatory response and present with fever, 
acute respiratory distress syndrome (ARDS), pleural effusions, renal failure, shock, and  
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myocardial depression. Metabolic complications include hypocalcemia, hyperlipidemia,  
hyperglycemia, hypoglycemia, and diabetic ketoacidosis. (82) 
Bacterial translocation: 
 The human gut barrier is compromised due to ischemia and pancreatitis-induced  
gut arteriovenous shunting, leading to translocation of bacteria resulting in local and  
systemic infection(83).  Local bacterial infection of pancreatic and peripancreatic tissues  
results in septic complications and multiorgan failure . 
CLINICAL FEATURES: 
 Acute pancreatitis is an important cause of acute upper abdominal pain and its 
clinical features are similar to a number of other acute illnesses. (84) 
 Symptoms — Almost all patients have recurrent attacks of acute upper abdominal 
pain at the onset . The pain is steady and may be in the mid-epigastrium, right upper 
quadrant, diffuse, or, to the left side.Pain can last for days. Its onset is rapid, reaching 
maximum intensity in many cases within 10 to 20 minutes. In about one-half of patients, 
pancreatic pain characteristically has band-like radiation to the back. Acute pancreatitis 
related to alcohol frequently occurs one to three days after a binge or cessation of 
drinking. Painless disease is uncommon (5 to 10 percent) and seen in the postoperative 
setting (renal transplantation), peritoneal dialysis, Legionnaire's disease. 
 The abdominal pain is typically accompanied ( 90 percent ) by nausea and 
vomiting, which may persist for many hours. Restlessness, agitation, and relief on 
bending forward are other notable symptoms. Patients with fulminant attacks may present 
in shock or coma.Patients with recurrent episodes of pancreatitis sometimes manage their 
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flares at home by staying on clear liquids for a few days.Hemorrhagic complications are 
rare including ecchymotic discoloration of the flanks or hemosuccus pancreaticus . 
Physical examination: 
 Physical findings vary depending upon the severity of an attack. Systemic features  
include fever, tachycardia, in severe cases, shock and coma. In mild disease, the  
epigastrium may be minimally tender. Severe episodes are often associated with  
abdominal distention, especially in the epigastrium, and tenderness and guarding. 
 Respiration may be shallow due to diaphragmatic irritation from inflammatory 
exudate, and dyspnea may occur due to associated pleural effusion.Ecchymotic 
discoloration in the flank (Grey-Turner's sign) or the periumbilical region (Cullen's sign) 
occurs in 1 percent of cases . Jaundice is usually the result of obstruction of the CBD.An 
epigastric mass due to pseudocyst formation may become palpable in the course of the 
disease. 
Less common features include subcutaneous nodular fat necrosis panniculitis,  
thrombophlebitis in the legs, and polyarthritis. The lesions of fat necrosis, 0.5  
to 2 cm tender red nodules, are usually located over the distal extremities .There may also  
be findings indicative of underlying disorders such as hepatomegaly in alcoholic  
pancreatitis, xanthomas in hyperlipidemic pancreatitis, and parotid swelling associated  
with mumps. 
LABORATORY TESTS: 
 Serum amylase— rises within 6 to 12 hours of onset, and is cleared fairly rapidly 
from the blood (half-life 10 hours). In uncomplicated attacks, serum amylase is usually  
elevated for three to five days except in hypertriglyceridemia-associated pancreatitis (39).  
 23
The serum amylase concentration in acute pancreatitis is usually more than three times  
the upper limit of normal but it may be normal or minimally elevated. 
 Hyperamylasemia may also be seen in diseases of  salivary glands and fallopian  
tubes ,intestinal infarction and perforated viscus and peritonitis , renal failure,  
cholecystitis, macroamylasemia. Analysis of amylase of pancreatic origin (P-isoamylase)  
which represents 35 -50 % of the normal serum amylase improves diagnostic accuracy.(85) 
 Serum lipase — Its sensitivity for the diagnosis of acute pancreatitis ranges from 
85 to 100 percent in various reports (85). Lipase is more specific than serum and urinary  
amylase in diagnostic accuracy both on day one and day three (86). Nonspecific elevations 
of lipase have been reported in almost as many diseases as amylase(87).  Lipase elevations 
occur earlier and last longer than amylase elevations. Studies found that the combination 
of enzymes does not improve diagnostic accuracy (88). Daily measurement of enzymes has 
no value in assessing the clinical progress or prognosis(87).  The level of pancreatic 
enzyme elevation does not correlate with severity  
BILE MICROSCOPY: 
 Microscopic examination of gall bladder bile is considered to be the diagnostic 
gold standard for detection of microlithiasis.Bile can be collected during ERCP or from 
the duodenum. However , the preferred method is collection of gall bladder bile by  
administering cholecystokinin.(19).  The collected bile should be immediately  
centrifuged and analysed. Cholesterol microcrystals are birefringent and rhomboid  
shaped and best seen on polarizing microscopy while biliruin granules are red brown and  
detected by conventional microscopes. 
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RADIOLOGIC FEATURES : 
 Abdominal plain radiograph—  excludes obstruction and bowel perforation.  
Radiographic findings are "sentinel loop" or the "colon cutoff  sign" and  generalized 
ileus .   
 Abdominal ultrasound —A diffusely enlarged, hypoechoic pancreas is the classic 
ultrasonographic image of acute pancreatitis.Ultrasound also detects  gallstones and 
image the biliary tree.25 to 35 percent have bowel gas that may obscure the 
pancreas.Ultrasound cannot clearly delineate extrapancreatic spread of pancreatic  
inflammation or identify necrosis within the pancreas.The accuracy of USG in detecting  
cholelithiasis is high and thesensitivity ranges from 92 to 96%. (89) When the stones are  
<3mm in diameter ,the sensitivity of USG is only 55 to 65%.(90) The sensitivity of USG  
for dilated CBD  is  55-90% and CBD stones is 50-60%.(89) 
 CT scan — the most useful imaging study for diagnosis of acute pancreatitis , 
intraabdominal complications and also for assessment of severity. Pancreatic  
necrosis is seen as unenhanced areas (less than 50 Hounsfield units after IV contrast)  
greater than 3 cm in size after oral and itravenous contrast.If there is suspicion of  
infection, analysis of contents obtained by CT or US guided needle aspiration can  
differentiate between sterile and infected pancreatic necrosis or a pseudocyst. 
CT abdomen useful to detect pancreas divisum and pancreatic tumors. But it is less  
accurate to identify gall stones(91) 
 Magnetic Resonance Imaging:  The advantages of MRI over CT include lack of 
nephrotoxicity of gadolinium, ability of MRI to better categorize fluid collection as acute 
fluid collections, necrosis, abscess, hemorrhage and pseudocyst, and the greater 
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sensitivity of MRI to detect mild acute pancreatitis compared to CT. MRI was reliable for 
staging the severity of AP, had prognostic value, and was associated with fewer 
contraindications compared to CT, and was able to detect pancreatic duct 
disruptions.Abdominal imaging using MRI is operator dependent with consequent 
variability in quality and technique.(92). 
 Magnetic Resonance Cholangiopancreatography: permits detailed anatomic 
images of pancreatic and bile ducts and produce an image similar to ERCP. In RIAP, the 
primary value of MRCP is to identify congenital anomalies of pancreatobiliary ducts such 
as pancreas divisum, choledochocele,  AUPBD,  and annular pancreas.(92)  
In the diagnosis of pancreas divisum, MRCP has been reported to be as good as or 
even superior to ERCP.(93) MRCP is also helpful for diagnosing or excluding  
choledocholithiasis and is comparable to ERCP(Sensitivity - 90%). (94)  However  
small gallstones (<5 mm) in the  biliary tree are easily missed.(95)  
Recently, dynamic MRCP, acquisition of multiple pictures at short intervals after  
intravenous secretin enhances visualization of the pancreatic ducts.(96,97).  
Costamagna et al. (35) used secretin-enhanced MRCP to document Santoriniceles in  
patients with idiopathic acute recurrent pancreatitis when compared with conventional  
MRCP. 
Persistent dilatation of  MPD with secretin-enhanced MRCP may  
identify functional outflow obstruction at major or minor duodenal papilla. (96)  
In the near future, MRCP may replace diagnostic ERCP for the evaluation of  
ductal anatomy.(97)  and  reserve the use of ERCP for a therapeutic procedures . 
The major advantage of MRCP is that it does not require endoscopy, contrast injection, or 
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radiation and is safe (98) in pregnancy and those with contrast allergy. 
 Endoscopic Retrograde Cholangiopancreatography:- can define anatomic or 
structural abnormalities by observing duodenal papilla and obtaining ductography.(99) and 
to collect bile for crystal analysis .The most frequently identified causes of unexplained 
pancreatitis after endoscopic evaluation are ampullary lesions, choledocholithiasis, gall 
bladder microlithiasis, pancreas divisum , AUPBD , annular pancreas, pancreatic cancer, 
SOD and chronic pancreatitis.   When bile is collected from CBD at ERCP, obtaining 
gallbladder bile with  cholecystokinin stimulation is ideal.(19).Bile aspiration after deep 
cannulation of CBD without cholecystokinin stimulation is more practical because it is 
simple and easy. 
 When bile collection, ductography, and sphincter of manometry (SOM) are 
performed in one session, studies are recommended to be carried out in the following 
order; bile collection, ductography, and lastly SOM.To  summarise , ERCP plays an 
important role in the management of RIP. The diagnostic yield of ERCP varies from 38% 
to to 79% . 
 Endoscopic Ultrasonogram: is an ideal minimally invasive tool for evaluation of 
unexplained pancreatitis.  It  may be used for identification of cholelithiasis , gallbladder 
sludge, CBD stones,(100) pancreatic tumors, chronic pancreatitis and ampullary lesions. 
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APPROACH TO DETERMINE ETIOLOGY OF RECURRENT PANCREATITIS:- 
 Evaluation of a patient after the first attack of pancreatitis includes a careful 
history , lab studies ( lipid profile ,serum calcium, ANA, LFT)  and USG abdomen. An 
USG should be repeated because multiple longitudinal examinations may be required to 
identify small gallbladder stones or sludge.(102,103) Approximately 20% to 50% of patients 
with acute pancreatitis will have a recurrence. (11,27,105,106) When a patient has a recurrent 
attack, invasive imaging studies should be performed because a diagnosis can be 
established in 38% to 76%.(101,105,107,108) 
 EUS  if available should be the next test as it can identify gall bladder sludge, 
small CBD  stones , pancreas divisum , pancreatic tumors and early chronic 
pancreatitis.If EUS is normal or not available , ERCP with SOM is recommended. 
In clinical practice, ERCP without SOM is commonly performed presumptively  
to exclude CBD stones, yet their prevalence is low in RIP (<10%) and much less frequent  
than SOD. Because of the substantial risk of pancreatitis after ERCP in patients with  
SOD, such a practice is discouraged unless clinical, laboratory,(103,104,109) and 
radiologic features strongly suggest choledocholithiasis as a likely cause.  
For patients with idiopathic acute pancreatitis, selective use of genetic testing may  
be appropriate. For the patient with RIAP, especially in the setting of an appropriate  
family history, genetic testing for cationic trypsinogen gene (PRSS1) is recommended  
(92) Other genetic abnormalities associated with idiopathic pancreatitis include 
mutation  of cystic fibrosis transmembrane conductance regulator gene (CFTR) and  
SPINK1 gene. The role of genetic testing for these mutations is less clear and   
controversial(70). 
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TREATMENT: 
GENERAL PRINCIPLES OF THERAPY:   
 Mild pancreatitis is treated with supportive care including pain control, 
intravenous fluids, and nothing by mouth.In severe pancreatitis, intensive care unit 
monitoring and support of pulmonary, renal, circulatory and hepatobiliary function may 
minimize systemic sequelae.Fluid resuscitation is particularly important and  around  250 
to 300 cc of intravenous fluids per hour are required for 48 hours. (110) 
 Preventing infection in severe acute pancreatitis :Three approaches have been 
taken to decrease bacterial infections in acute necrotizing pancreatitis : Enteral feeding , 
selective decontamination of the gut with non-absorbable antibiotics and prophylactic  
systemic antibiotics. Guidelines from the American Gastroenterological Association  
(AGA) (110) recommended antibiotics for patients with >30 percent pancreatic  
necrosis. Due to the conflicting data, the use of prophylactic imipenem/meropenem in  
severe acute pancreatitis, with significant necrosis and/or organ failure, continues to be  
debated. 
 Nutrition: Nutritional support is required for patients with severe pancreatitis. 
Parenteral feeding is recommended if there is ileus.Enteral feeding should be started to 
reduce systemic complications.Three meta-analysis of enteral nutrition suggest improved  
outcomes compared with parenteral nutrition(111). Human studies have shown  
that continuous feeding in the distal jejunum does not stimulate exocrine pancreatic  
secretion(112) 
 Open surgical debridement:- is recommended for patients with infected necrosis  
and those deteriorating with conservative management.(84).  
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 Experimental agents:—Data suggests that there is no role for proteinase inhibitor  
gabexate mesilate, somatostatin and its analogue octreotide (113,114,115) and  platelet  
activating factor antagonist,lexipafant in therapy of RAP.(116)  Correcting underlying  
predisposing factors of pancreatitis is very important to prevent recurrence. 
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METHODOLOGY 
A. RETROSPECTIVE ANALYSIS OF PATIENTS WITH RECURRENT ACUTE 
PANCREATITIS (RAP): 
STUDY DESIGN: 
Retrospective descriptive study. 
 Retrospective analysis of patients diagnosed to have recurrent acute pancreatitis 
attending Christian Medical College Hospital, Vellore during the period January 2002 to 
December 2007 (5 years). 
SUBJECTS: 
 188 patients with two or more episodes of acute pancreatitis were included in the  
analysis. 
 
DEFINITIONS: 
Diagnostic criteria for recurrent acute pancreatitis(8)  
( i )  Two or more documented episodes of  typical pancreatic type of  abdominal pain  
 more than two  months apart. 
(ii )  Amylase or lipase greater than 3 times the upper limit of normal and / or 
(iii )  Features of acute pancreatitis on imaging studies ( Ultrasound / CT abdomen ) 
 Criteria for Severe Acute Pancreatitis(7)– Acute Pancreatitis with one or more of 
the following: 
Local complications: pancreatic necrosis, abscess or pseudocyst,   
Systemic organ dysfunction: respiratory  failure ,  renal failure,shock .  
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 Biliary pancreatitis: Pancreatitis with one or more of the following: ( i )Clinical 
jaundice or  elevated serum bilirubin ( direct bilirubin>50% of total bilirubin), (ii) elevated 
ALT, AST, ALP,(iii) dialatation of  bile duct  , gallstone or sludge in the gall bladder , 
common bile duct stone by ultrasound /CT abdomen / ERCP / MRCP imaging (iv) 
microlithiasis on bile duct / duodenal bile sampling . 
 Alcohol induced pancreatitis: Pancreatitis in a person consuming an average of 80 
g alcohol taken daily for more than 5 years or an alcoholic binge  taken immediately before 
the acute attack. 
 Hyperlipidemia induced pancreatitis: Pancreatitis with serum triglyceride more 
than 500mg /dL). 
 Hypercalcemia induced pancreatitis: Pancreatitis with fasting serum calcium equal 
to or more than 10.5 mg /dL (hospital reference values).  
 Idiopathic pancreatitis: No etiology detected on history, clinical examination , 
laboratory tests , radiological tests,bile sampling or ERCP . 
 
EXCLUSION CRITERIA: 
 All patients diagnosed to have chronic pancreatitis on  ultrasound  /  CT abdomen 
(intraductal or parenchymal calcification or dilatation of pancreatic duct , atrophy of 
pancreas )  or ERCP  (abnormal main pancreatic duct  or  > 3 abnormal side branches) 
were excluded. 
ANALYSIS: 
 Clinical profile, etiology, complications and response to therapy were analysed. 
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B. GENETIC STUDIES IN RECURRENT ACUTE PANCREATITIS (RAP): 
 Seventeen patients with recurrent acute pancreatitis were prospectively analysed for 
known genetic mutations or polymorphisms in PRSS1, PRSS2, SPINK1 and Cathepsin B 
genes. 
GENETIC ANALYSIS: 
DNA  extraction using manual method for RAP:      
 10 ml of peripheral blood was collected in an EDTA tube and centrifuged at 4000 
rpm for 10 minutes at 4˚C. The buffy coat was transferred to a fresh tube to which  10-15 
ml of RBC lysis solution was added and incubated in ice for 10 minutes (a). The mixture 
was centrifuged at 4000 rpm for 10 minutes at 4˚C and the supernatant discarded (b). The  
steps (a) and (b) are repeated to obtain a clear white pellet. 4.5 ml WBC lysis solution , 
250µl of 10% SDS and 100 µl of 10mg/ml proteinase K are added to this pellet and 
incubated at 37˚C overnight. After the lysis is complete, 1.5ml  6M NaCl is added along 
with an equal volume of chloroform and centrifuged at 4000 rpm for 30 minutes for 4˚C. 
The upper layer is taken and suspended in 5ml saturated phenol and shaken well. This is 
centrifuged at 4000 rpm for 30 minutes at 4˚C. The supernatant is taken and suspended  
in chloroform : Octanol (24:1) and centrifuged at 4000 rpm for 30 minutes at 4˚C. To the 
supernatant, double the volume of absolute alcohol is added in a separate tube and then 
the supernatant is suspended in alcohol. This is mixed gently  and the pellet is transferred 
into 70% ethanol in a micro centrifuge tube. After the pellet is transferred into 100-300 µl 
1XTE buffer with a  pH  of 7.4.and  stored at 4˚C. 
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DNA extraction using isolation kit for control samples: 
 Blood samples were collected in EDTA tubes from peripheral vein and stored at –
20 °C. DNA was isolated from this whole blood using the Pure Gene DNA isolation kit 
according to the instructions from the manufacturer (Gentra Systems, Minneapolis, 
Minnesota, USA). DNA was diluted to a concentration of 50 milligram per millilitre and 
stored at 4 °C. 
PCR- Polymerase Chain Reaction: 
 PCR was performed in 25 mL with 250 ng of genomic DNA, a mixture 
containing 50 mmol/L Tris.HCl, pH 9.2, 2.25 mmol/L magnesium chloride (MgCl2), 
7.5% DMSO, 16 mmol/L (NH4)2SO4, 250 mmol/L each of dGTP and deazadGTP, 500 
mmol/L of the other dNTPs, and 3.3 U of Expand Long Template DNA polymerases 
(Roche Diagnostics, GmbH, Mannheim, Germany). After 5 minutes of denaturation at 
94°C, 30 cycles were performed at 94°C for 40 seconds, an annealing temperature (Table 
A) for 30 seconds , and 72°C for 30 seconds for 30 cycles, with the final extension of 
72°C for 7 minutes and the programme ends. The Oligonucleotides used are given in the 
table below. Table A 
Mutation Oligonucleotides Ann. 
temp 
N34S 5’TTCTGTTTAATTCCATTTTTAGGCCAAATGCTGCA
3’ 
5’GGCTTTTATCATACAAGTGACTTCT3’ 
56 
N29I 5’CCATCTTACCCAACCTCAGTAG3’ 
5’TGATGACAGATCGTTGGGGGCTAGA 3 
56 
R122H 5’GGTCCTGGGTCTCATACCTT3’ 
5’GTAATGGGCACTCGAAATGT3’ 
52 
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Conformation sensitive gel electrophoresis (CSGE): 
For control analysis, 3µl of heteroduplexed control samples were mixed with 
1.5µl of loading buffer (70% glycerol, 0.1% Xylene cyanol, 0.1% Bromophenol blue, 
0.01% 1M EDTA) and electrophoresed in a mildly denaturing gel (400x330x1mm in 
size) containing 10% Acrylamide  {99.1 Acrylamide (Invitrogen Lifetechnolgies, 
Groningen, Netherlands): Bisacrolylpiperazine (Fluka Chemie, Buchs, Switzerland)}, 
10% ethylene glycol (Sigma, St.Louis, USA), 15% Formamide (Sigma, St.Louis, USA) 
and 0.5X TTE buffer [20X TTE -1.78 M Tris (USB, Ohio, USA), 570mM Taurine (USB, 
Ohio, USA) and 4mM EDTA (USB,Ohio,USA)]. Polymerization was achieved by the 
addition of 0.1% Ammonium persulphate (USB, Ohio, USA), and 0.07% N, N, N’, N’ –
Tetramethylethylenediamine (TEMED) (Sigma, St.Louis, USA). Following 
electrophoresis at 400V for 18 hours, bands were visualized by ethidium bromide 
staining.  
 We employed two different assays for detection of the PRSS2 G191R allele.  
 Method A. Real time detection: A dual-colour allele-specific discrimination assay 
for genotyping the exon 4 mutation at codon 191 of the PRSS2 gene was using the 
iCycler iQ Multicolour Real-Time Detection System (Bio-Rad Laboratories) with 
molecular beacons. PCR was performed with the forward primer 5’-CTA TTG TCT CTT 
TCT CTG GCC TA-3’ and the reverse primer 5’-GCC ACC TTG GGA GTT CAA ATC 
A-3’ in the presence of the developed molecular beacons, FAM- labeled wild-type 
beacon (5’-CGC GTC ATC CTT GCC TCC CTC GAG GAA GCC GAC GCG-3’) and 
the HEX-labeled mutant beacon (5’- CGC GTC ATC CTT GCC TCT CTC GAG GAA 
GCC GAC GCG-3’). The 25 microliter reaction mixture contained 200 ng of genomic 
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DNA, 10 mM Tris/HCl (pH 9.0), 50 mM KCl, 0.1% Triton X-100, 4 mM MgCl2, 0.25 
mM dNTPs, 5 pmol of each primer, 200 nM of each beacon and 2.5 U Taq-DNA-
polymerase. The PCR conditions were 3 min at 95°C, then 40 cycles of 30 s at 95°C, 30 s 
at 59°C and 30 s at 72°C. Fluorescent signals were measured at 59°C (Figure III). 
Genotypes were assigned using the iCycler iQ Optical System Software version 3.1.  
 Method B. Melting curve analysis: We performed melting curve analysis for the 
G191R alteration using a pair of fluorescence resonance energy transfer (FRET) probes 
and the LightCycler (Roche Diagnostics). Primer for PCR of exon 4 are described above. 
The donor probe was 5'-CAGGAATCCTTGCCTCCCTC-FL (FL: 5,6-
carboxyfluorescein attached to 3'-O-ribose) and the acceptor probe was 5'-LC-
AGGAAGCCCACACAGAACATGTTGTTG-ph (LC: LightCycler Red 640 attached to 
5' terminus; ph: 3' phosphate). The donor probe was complementary to the wild-type 
sequence. During melting curve analysis, a more stable duplex with the wild-type allele 
than with the mutant allele was formed, resulting in an allele-specific melting curve (62.5 
°C vs. 56 °C).  
Melting curve analysis:  
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DNA Sequencing: 
DNA sequencing was performed using Sanger’s dideoxy DNA with fluorescently 
labelled dideoxy nucleotide triphosphates using the Big Dye Terminator cycle 
sequencing kit V 1.1 or V3.1 (Applied Biosystems, Foster City, CA) in an automatic 
sequencer ABI 310 (Applied Biosystems, Foster City, CA). The PCR products were 
purified using a PCR clean up system (Millipore, Bedford, MA) and cycle sequencing 
reaction was set up using the purified product. After the cycle sequencing reaction, the 
product was again purified using post PCR clean up kit (Millipore, Bedford, MA) and 
loaded in the genetic analyzer. All the nucleotide changes identified were confirmed by 
repeating the PCR, CSGE and sequencing reactions. 
( i ) SPINK 1 mutations (N34S, P55S):  
 PCR was performed on Exon3 of SPINK 1 gene. N34S and P55S mutations were 
identified after sequencing the PCR product in ABI310 genetic sequencer. 
( ii ) PRSS1 MUTATION (N29I & R122H) : 
 Cationic trypsinogen gene (PRSS1) mutations like R122H and N29I were 
analysed using PCR and direct DNA sequencing.  
(  iii ) PRSS2 mutation (G191R)- Real time detection in Cohort-I: 
 A dual-colour allele-specific discrimination assay for genotyping the exon 4 
mutation at codon 191 of the PRSS2 gene using the iCycler iQ Multicolour Real-Time 
Detection System (Bio-Rad Laboratories) with molecular beacons (figure III).  
( iv) PRSS2 mutation(G191R)- Melting curve analysis for Cohort II:  We performed 
melting curve analysis for the G191R alteration in cohort II using a pair of fluorescence 
resonance energy transfer (FRET) probes and the LightCycler (Roche Diagnostics).  
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Cathepsin B gene: 
 The exon 3 and Exon 4 and the exon intron boundary of    cathepsin B was 
analysed using the oligonucleotides as shown in Table 9.1. Amplified PCR products were 
subjected to direct DNA sequencing using ABI310 genetic analyzer  
CONSENT : 
 Informed written consent (Annexure1) was taken for blood collection and DNA 
analysis prior to the study. Peripheral blood sample (10 ml) was collected from the 
antecubetal vein using K3EDTA coated vacutainer tubes (VACUTTE). This blood was 
stored at -20 degree celsius . Genetic studies were performed at Wellcome Research  
Laboratory, CMC, Vellore. 
STATISTICAL ANALYSIS:  
 Data was analysed by statistical software SPSS (Statistical Package for Social 
Sciences, release 11.0, standard version; SPSS Inc). 
 This was a retrospective descriptive study and data was reported as means with 
standard deviation or median with ranges for continuous variables and as frequencies and 
percentages for categorical variables. 
 For continuous variables , t test was used for normally distributed variables and 
Mann Whittney test for non normally distributed variables.The results between groups 
were subjected to Chi-Square tests to assess for significance of genetic mutations and 
treatment modalities. A p value of less than or equal to 0.05 was considered statistically 
significant. 
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RESULTS 
Age Distribution: 
 The mean age of  patients was 32.6 years (13.9SD), the youngest being 6 years  
and the eldest  76 years . 
 There were 84 (44.6%) patients below 30 years and 104 (55.3%) above 30 years. 
Mean age of males was 34.0 years and females 29.3 years 
Sex Distribution:  
 132 (70.2%) patients were males and the rest  56(29.8) females , the male: female  
ratio being     2.3 : 1                    . 
 32 females were < 30 years and 24 were > 30 years of age. 
 52 males  were  < 30 years while 80 were > 30 years of age. 
Geographic Distribution: 
 126 ( 67.02% ) were from the East of India ; 44 patients ( 23.40%) from South  
and 18 ( 9.57% ) from North of  India, reflecting patient profile visiting CMC. 
Number of episodes of pancreatitis: 
 The number of episodes of recurrent acute pancreatitis in patients is shown in the  
Table : I .Majority of  the patients (38.3%) had 2 episodes while 4 had 10 episodes of  
pancreatitis.  The mean number of attacks were 3.53. 
Table I. Episodes of pancreatitis 
Episodes of pancreatitis        No: of patients(%) 
    2            72(38.3%) 
    3---4            58(30.9%) 
    5—6            49(26.1%) 
    8—10            9(4.7%) 
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Symptoms: 
 All patients presented  with  abdominal pain ;159 patients (84.6%) had vomiting 
72 patients (38.3 % ) had constipation and jaundice was seen in 28(14.9%) patients. 
Laboratory Tests: 
 Serum calcium was estimated in 185 patients. 5 patients ( 2.7 %) had calcium 
levels more than 10.5 mg /dL. Serum cholesterol and triglycerides were done in 175  
patients . 6 (3.2%) patients had triglyceride levels higher than 500 mg/dl. 
Biliary Microliths : 
  60 (31.9%) patients had sludge in gall bladder or microlithiasis in the bile 
aspirated either from bile duct or from the duodenum adjacent to the ampulla. 
Etiology: 
Etiology of RAP is shown in Table II. 
Table II. Etiology 
Etiology Number % 
Biliary  90 47.9 
----Gall stone/CBD stone  38 20.2 
----Sludge/microlithiasis  52 27.7 
Structural 29 15.4 
----Pancreas divisum  17 9.1 
----Papillary stenosis  6 3.1 
----Anomalous pancreato biliary   3 1.6 
----Suprapuppillary duodenal diverticulum  3 1.6 
Alcohol  20 10.6 
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Metabolic 11 5.9 
----Hypercalcemia  5 2.7 
----Hypertriglyceredemia  6 3.2 
Trauma  3 1.6 
Idiopathic 34 18.1 
Ascariasis                                 1 0.5 
         Total 188 100 
 Region wise distribution of etiological factors in RAP are shown in Table III.  
Etiological profile were grossly similar in patients from East,South and North of India. 
Table III. Etiology (Region wise) 
Etiology East (n-126) South (n-44) North (n-18) 
Biliary  62 (49.2 %) 21( 47.65 %) 7 (38.89 %) 
Alcohol 10 (7.93 %) 8 (18.18 %) 2 (11.11 %) 
Idiopathic  24 (19.4 %) 5 (11.36 %) 5 (27.78 %) 
Others 30 (23.8 %) 10 (22.73 %) 4 (22.22 %) 
 
 The most common etiology was biliary in 90 patients(47.9%) which included gall 
stones,CBD stones gall bladder sludge and microlithiasis.Structural causes like  
pancreas divisum, papillary stenosis, anomalous pancreato-biliary  union  and   
suprapapillary  duodenal  diverticulum were seen in 29 patients (15.4%).Metabolic  
causes like hypercalcemia and hypertriglyceredemia were seen in 11 patients(5.9%).  
34 patients (18.1%) in whom no etiological factor was identified were labelled  
Idiopathic. Multiple etiological factors were detected in 24(12.8%) of patients. 
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Details are shown in Table 1V. 
Table IV: Multiple etiologies. 
Etiologies  No.of patients Therapy Response /            
No response 
Microliths + PD 1 Sphincterotomy. Response  
Microliths + PS 1 Sphincterotomy. No response 
Microliths + HTGL 1 Niacin Developed CP 
Microliths + 
Alcohol 
5 Sphincterotomy(2) 
UDCA (2)             Lost 
to FU (1) 
Response (1) 
Response (2) 
Alcohol+HTGL 1 Lost to FU - 
Alcohol+gallstones 6 Sphincterotomy and 
stone extraction(4) 
Conservative (2) 
Response (4)            
On FU 
PD + gall stones 3 Bil.sphincterotomy(3) Response     (2) 
No response(1) 
Hypercalcemia+PD 1 Antioxidants  On FU 
Hypercalcemia + 
gall stones 
1 Conservative  On FU 
Hypercalcemia 
+PD+gall stones 
1 Bil sphincterotomy Response 
APBU+PD 1 Bil sphincterotomy Response  
APBU+microliths 1 UDCA Response  
APBU+choledochal 
cyst 
1 Surgery  Response. 
 
(PD:pancreas divisum,PS:papillary stenosis,APBU:anomalous pancreatic biliary 
union,FU:follow up,HTGL:hypertriglyceridemia) 
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Complications: 
Complications are shown in Table V. 
Table V.  Complications: 
  Complications Number          % 
  Pseudocyst  14        7.4 
  Necrosis   3        1.6 
  Abscess   3        1.6 
 Psudoaneurysm   1        0.5 
 Venous thrombosis   
      Splenic Vein thrombosis  8       4.3 
      Superior Mesentric Vein thrombosis  3      1.6 
      Portal Vein thrombosis  1      0.5 
 Most common complication was pseudocyst seen in 14 patients 
(7.4%).Thrombosis of portal venous system was seen in 12 patients(6.4%) 
TREATMENT AND RESPONSE: 
Drug Therapy: 
 Patients detected  to have microlithiasis were given a trial of  
ursodeoxycholic acid  for 6 months. A subset of patients with idiopathic RAP  were  
also given a trial of UDCA to assess  response. Table  V1  shows  details of response  
to UDCA therapy. 76 % of patients with microlithiasis and 40 % of patients with  
idiopathic RAP responded to UDCA. 
   Thirteen patients diagnosed as idiopathic RAP were given an empiric  
trial of pancreatic enzyme therapy suspecting early chronic pancreatitis. Details of  
response are shown in the Table  VI . 39% of patients with idiopathic recurrent  
 43
pancreatitis responded to pancreatic enzyme supplements. Duration of follow up  
ranged from 6 months to 4 years. 
Table-V1.   Medical therapy. 
             Drug No. Responded to 
therapy(%) 
No response Lost to follow up 
 Ursdeoxycholic acid     
        Microlithiasis  41   31(75.6)  8    2 
        Idiopathic  10     4(40)   4    2 
Pancreatic enzymes     
        Idiopathic  11    5(38.5)  3    5 
 
Endotherapy: 
 Biliary sphincterotomy and stone extraction was performed for patients with  
choledocholithiasis. Biliary sphincterotomy was performed for patients with  
microlithiasis  responding  to a trial of UDCA, those with papillary stenosis and a  
subset of patients with idiopathic RAP. Accessory papillary sphincterotomy was  
performed for patients with pancreas divisum. Details of response to endotherapy  
are shown in the Table VI1. 
 67% patients with microlithiasis and 50 % of idiopathic RAP responded to biliary  
sphincterotomy. Majority of patients with pancreas divisum (73%) responded to  
accessory papilla sphincterotomy. 
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Table VI1. Endotherapy. 
          Endotherapy Number Response(%) No 
response 
Lost to 
follow up 
 Biliary sphincterotomy     
            Microlithiasis/sludge  36    24(66.7)    9    3 
      Papillary stenosis    2      2(100) - - 
      Idiopathic  12      6(50)   3   3 
Accessory Papilla  
sphincterotomy 
    
     Pancreas divisum  11      8(72.7)   3 - 
 
Surgery: 
 Cholecystectomy  was performed in patients with gallbladder stones. 
Necrosectomy was  performed in 3 patients and pseudocyst drainage in 6 patients. 
Follow Up: 
 Mean follow up period was 3 years ;  56 patients (29.8%) were lost to follow up.   
23 patients (12.2% ) developed chronic pancreatitis during follow up- 
14 patients within 1 year of presentation ; 5 patients in 2 years ; 2 in 3 years  
and one each in 4 and 5 years,.  9 (39.1%) of idiopathic pancreatitis, 5 (21.7%)  
with pancreas divisum , 4 ( 17.3%) with biliary microliths , 2 (8.7%) with    
hypercalcemia and  1 (4.34%) each with alcohol , papillary stenosis and   
hypertriglyceridemia progressed to chronic pancreatitis. 
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Mortality: 
 27  (14.36% ) patients had severe pancreatitis . 
 The etiology among these patients were Idiopathic pancreatitis in 10 (37.04%) , 
biliary(7 gall stones and 3 microliths ) in 10 (37.04%) patients, alcohol , pancreas  
divisum in  3 (11.1%) each , and papillary stenosis in 1 (3.7%) patient . 
4(15%)developed chronic pancreatitis (idiopathic :3 , pancreas divisum:1) 
There was no mortality in the group of patients studied. 
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GENETIC STUDIES: 
 Genetic analysis done in a subset of 17 patients is shown in Table VII1. 
Table VII1: 
REGION POLYMORPHISM PATIENTS 
(n - 17) 
CONTROLS 
( n – 150) 
SIGNIFICANCE
 
Exon 3 
 
PRSSI (R122H) 
 
0 
0 
 
- 
Exon 2 PRSSI (N29I) 0 0 - 
Exon 4 PRSS2 (G191R) (+/-) 0 3(2.2%)  
Exon 3 SPINK1((N34S) (+/-) 0 6(4.5%) 0. 62 
Exon 3 SPINK1 (N34S) (+/+) 0 1(0.7%)  
Exon 3 SPINK1 (P55S) (+/-) 0 3(2.2%) 0.77 
Exon 3 SPINK1 (P55S) (+/+) 0 1(0.7%)  
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Cathepsin B genotypes:  
Exon  POLYMORPHISM PATIENTS CONTROLS SIGNIFICANCE
Exon 3  C12T (+/-) 0 28 (20.9%) 0. 04 
Exon 3  C76G (+/-) 8 (47.1%) 58 (43.3%) 0.76 
Exon 3  C76G (+/+) 1 (5.9%) 16 (11.9%)  
Exon 3  T663C (+/-) 1(5.9%) 30 (22.4%) 0.13 
Exon 3  T663C (+/+) 0 8 (6%)  
Exon 3  C173G (+/-) 0 1 (0.7%) 1.0 
Exon 3  C182T (+/-) 0 1 (0.7%) 1.0 
Exon 3  G205C (+/-) 0 0  
Exon 3  T232G (+/-) 0 0  
Exon 3  C261T (+/-) 0 2 (1.5%) 1.0 
Exon 3  G265T (+/-) 0 3 (2.2%) 1.0 
Exon 3  G274C (+/-) 0 3 (2.2%) 1.0 
Exon 3  G394A (+/-) 0 6 (4.5%) 1.0 
Exon 3  A335T (+/-) 0 33 (24.6%) 0. 05 
Exon 3  A335T (+/+) 0 4 (3%)  
Exon 3  C412T (+/-) 0 1 (0.7%) 1.0 
Exon 3  G426C (+/-) 0 0  
Exon 3  G460C (+/-) 0 1 (0.7%) 1.0 
Exon 3  A505T (+/-) 0 1 (0.7%) 1.0 
Exon 3  G513A (+/-) 0 2 (1.5%) 1.0 
Exon 3  G575T (+/-) 0 2 (1.5%) 1.0 
Exon 3  C595T (+/-) 0 1 (0.7%) 1.0 
Exon 3  A608C (+/-) 0 1 (0.7%) 1.0 
Exon 3  G642C (+/-) 0 1 (0.7&) 1.0 
Exon 4  A790G (+/-) 3 (17.6%) 13 (9.7%) 0. 57 
Exon 4  A790G (+/+) 0 1 (0.7%) - 
Exon 4  G834C (+/-) 1 (5. 9%) 0 - 
 
 None of the patients showed mutation in PRSS1 (R122H ; N29I),PRSS2 (G191R)  
and SPINK1 (N34S ; P55S) genes. 
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 Few control subjects showed heterozygous and homozygous mutations in 
SPINK1 (N34S and P55S )  and PRSS2 (G191R) genes. 
 Analysis of cathepsin B gene showed 4 polymorphisms in patients with RAP. 
(Exon 3:C76G, T663C; Exon 4 : A790G, G834C ) and 18 polymorphisms in the  
controls.(Table VII). C12T and A335T polymorphisms on Exon 3 were significantly  
more common in controls as compared to patients. 
 49
CATHEPSIN B GENE ELECTROPHEROGRAM: 
1. C76G (+/-) 
 
 
2. C76G (+/+) 
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3. A335T(+/+) 
 
 
4. A335T(+/-) 
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5. C12T(+/-) 
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DISCUSSION 
 The current study is a retrospective analysis of 188 patients diagnosed to have 
RAP over a 5 year period. Numerous studies have been published on acute and chronic  
pancreatitis , but few have focused on recurrent acute pancreatitis. RAP therefore 
still remains a clinical and diagnostic problem. 
Demography: 
 The mean age of  patients was 32.6 years (13.9SD), the youngest being 6 years  
and the eldest  76 years . Mean age of patients in the studies done by Wang et al (9)   
and Gullo et al (11), were  41 years and 43 years  respectively. The slightly older age  
of presentation in the above studies may be due to alcohol etiology in majority of  
patients.Majority of the patients( 70.2%) were males  which was similar to the  
studies by Wang (63%) and Gullo (78.8%).  57 %  of  females  were less than 30  
years of age while 60.6 %  of males were more than 30 years of age. 
 Majority of the patients ( 67%) were from Eastern  parts of  India ; 23.4% from  
South and 9.6 % from North India. This reflects the profile of patients visiting CMC  
for treatment and suggests that RAP is seen all over the country. 
 72 patients (38.3%) had relapsed twice,while rest of them had more than 2 
episodes.  This was similar to the study of Garg (117-119) et al but differed from the study 
by Gullo et al who showed that 70.7% of patients with alcoholic RAP and 80.6% with 
gall stones had 2 attacks. 
 The most frequent symptom  was abdominal pain (100%) followed by vomiting     
(84.6 % ) and ileus (38.3 % ) .which was identical to other studies . 
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Aetiology:  
 The most common aetiology  was biliary seen in  90 patients ( 47.9% ) which  
included  gall  stones , CBD stones , gall bladder sludge and  microlithiasis .  
52 (27.7%) had biliary microliths / sludge  and  38 (20%) biliary stones. Region wise  
analysis showed similar frequency of biliary pancreatitis in East , South  and North  
India.(East  : 49.2%; South :  47.5%; North : 38.9%). This is surprising because  
Tandon (118,119) found that North Indians and Bengalis have 2-4 fold higher  
prevalence of  gall stones compared  to South Indians. Our data differs from  
Western data where alcohol was the most frequent cause of RAP seen in 57 % of  
patients . 20 (10.6%) patients in the current study had alcohol related RAP. Biliary  
disease and alcohol had a combined  frequency of 58.5 % which was lower than  
Western data where the combined frequency was about 70%. (11) 
 Structural abnormalities of the pancreas were seen in 29 patients (15.4%). 
Pancreas divisum was the most common structural abnormality seen in 9%. This is lower 
than  the Western data where pancreas divisum is implicated as a cause of  
pancreatitis in 20% of the patients (125).Metabolic etiology was seen in 11 patients 5.9%);  
5 patients had hypercalcemia  and 6 hyperlipidemia. No etiology was detected in 34 
patients (18.1%) and they were labelled as idiopathic RAP . This is similar to the 
published data  where 10-25 % of patients with RAP have no identifiable cause and are 
termed idiopathic. Zhang et al (10) studied 77 RAP patients and found 48 (62.33%) had 
biliary pancreatitis,  
 3 (3.89%) had alcohol-induced pancreatitis, 3  (3.8%) had hyperlipidemic  
pancreatitis, and 21 (27.27%) had idiopathic pancreatitis. 
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 Region wise distribution of etiological factors were grossly similar in patients 
from East, South and North of India. 
 Multiple  etiological factors were detected in  24(12.8%) of patients.Deciding 
which factor is responsible for RAP may sometimes be difficult. Response of the patient 
to empirical therapy directed towards the probable cause confirms the cause of  
pancreatitis. 
Morbidity and Mortality: 
 14 (7.4%) patients had pseudocysts ,12 (6.4%) had venous thrombosis , 3 (1.6%) 
had pancreatic necrosis  and  pancreatic abscess . One patient had hemorrhage into  
the pseudocyst confirmed and treated by angiography. 
Wang (9) noted several complications which in descending order of  
frequency,were pancreatic pseudocyst, pancreatic ascities and bacterial peritonitis,  
pulmonary infections, multiple organ failure and shock. 
 There was no mortality in the patients studied . In the study by Gullo et al (11)   
5.9% died ,all of whom had necrotizing pancreatitis. Most of the deaths occurred  
during the  second attack of pancreatitis .They also found that the morbidity in  
necrotizing recurrent alcoholic pancreatitis was significantly lower than in patients  
with necrotic biliary (30%;p<0.0002) and necrotic idiopathic pancreatitis  
(25%;p<0.04). In the present study severe acute pancreatitis was detected more  
often in biliary and idiopathic pancreatitis(37%)as compared to alcoholic  
pancreatitis(11%) 
Absence of mortality in our study could be because most of our patients  
(85.6%) had mild pancreatitis and  only  14.4% had severe pancreatitis requiring  
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prolonged hospital stay and surgical treatment.  
Medical Therapy: 
Therapy directed at specific underlying cause will reduce recurrence rate of  
pancreatitis. Ursodeoxycholic acid (UDCA) may help to dissolve the cholesterol  
crystals (microliths ) and prevent recurrent attacks of pancreatitis.Three therapies  
have been used in relapsing acute and chronic idiopathic pancreatitis –  
antioxidants,pancreatic enzymes and octreotide.(120) 
In a small study of pancreatic enzyme therapy,12 patients with RAP had  
response rate (>50%reduction in frequency of attacks) of 75% . There is only a  
single trial using antioxidants in 5 patients with RAP. No conclusions can be drawn  
from this study because of the small number of patients.There is no data using  
octreotide in RAP. Conclusions on the efficacy of above therapy are difficult  
because of lack of large, placebo controlled trials with long term follow up.(120) 
Details of response to therapy to UDCA in patients with microlithiasis and  
response to pancreatic enzyme therapy in idiopathic RAP  are shown in Table V.  
41 patients detected to have microlithiasis were given a trial of UDCA  for 6 months.  
31 (76%) had relief of symptoms , 8 had no response and 2 were lost to follow  
up . These data confirm the results of other studies that microlithiasis is a frequent  
cause of recurrent acute pancreatitis. (21,118). The reason for recurrent pancreatitis  
in those on UDCA may be due to calcium bilirubinate crystals in bile, inadequate 
dosage of UDCA or irregular therapy.  
 All the 31 patients who responded to UDCA underwent biliary sphincterotomy as  
maintenance therapy is required to prevent recurrent stone formation. 
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13 patients diagnosed as idiopathic RAP were treated with pancreatic  
enzyme  therapy and followed up for 6 months to 4 years. 5 (38.5%) responded, 3  
had no response and 5 patients were lost to follow up. 10 patients with idiopathic  
RAP were treated with UDCA in the hope that undiagnosed microliths may be  
responsible for RAP in some of these patients. 4 (40%) responded , 4 had no  
response and 2 were lost to follow up.The numbers are small and no conclusions can  
be reached. 
Endotherapy: 
There is evidence to suggest that pancreatic duct obstruction can lead to  
acute pancreatitis.Rationale of endoscopic therapy is to relieve obstruction and  
prevent further episodes of pancreatitis.Endoscopic therapy has been shown to be  
beneficial in patients with RAP due to choledocholithiasis,biliary microlithiasis ,  
sphincter of Oddi dysfunction,pancreas divisum,choledochocoele and ampullary 
tumors.There is however a paucity of controlled data regarding outcomes in  
patients undergoing endoscopic therapy in RAP. 
Biliary sphincterotomy and stone extraction was performed for all patients  
with choledocholithiasis.Biliary sphincterotomy was performed on 36 patients with  
biliary sludge/microliths including 31 patients who responded to UDCA. 24 (66.7%)  
responded , 9 had no response and 3 were lost to follow up. This is similar to data  
from other studies with a response rate of 67 to 100 percent. (108,121 ) 
 Biliary  sphincerotomy was performed in 12 patients with idiopathic RAP. 6 
(50%) responded , 3 had no response and 3were lost to follow up.These data suggest that  
patients who had response to biliary sphincterotomy may have occult microlithiasis  
 57
or sphincter of Oddi dysfunction. Sphincter of Oddi manometry was not performed  
in this study . 2 patients with papilary stenosis had good response to biliary  
sphincterotomy. 
Accessory papilla sphincterotomy was performed in 11 patients . 8 (73%)  
responded while 3 continued to have recurrent attacks of pancreatitis .These results  
are comparable to data from other studies which show that endoscopic therapy of  
pancreas divisum decreases the rate of recurrence of pancreatitis in 70-90 % of  
patients when followed up for 5 years .(122-124) 
Surgery: 
14 patients with gall stones had cholecystectomy,  3 patients had  
cystogastrostomy and 3 necrosectomy and pseudocyst drainage. 
Chronic Pancreatitis on Follow Up: 
Patients initially diagnosed to have RAP ,may develop chronic pancreatitis.  
One reason could be the low sensitivity of ERCP to diagnose early chronic  
pancreatitis.Pancreatic function test (secretin stimulation) and EUS may be more  
sensitive to detect early chronic pancreatitis. Another possibility could be  
development of chronic pancreatitis following recurrent attacks of acute  
pancreatitis. 
23 (12.2%) patients developed chronic pancreatitis in 1 - 5 years during  
follow up. Initial diagnosis of these patients were as follows: Idiopathic pancreatitis:  
9 (39%) , pancreas divisum : 5 (22%) , biliary microliths : 4 (17%) , hypercalcemia : 
2 (9%) , alcohol,papillary stenosis ,hypertriglyceridemia : 1 (4%) each. 
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Does Idiopathic RAP really exist? 
After extensive evaluation including history , laboratory tests , imaging  
( ultrasound / CT scan) , ERCP  and  bile for microlithiasis , no etiology could be  
detected  in  34 (18 %)  patients.and they were labeled as Idiopathic RAP. 11 (32%)  
responded to empirical trial of UDCA or biliary sphincterotomy and had no  
relapses for at least one year suggesting that these patients may have occult  
microlithiasis or SOD. 9 (26%) developed chronic pancreatitis on follow up of 1-5  
years . 11 (32 %) were lost to follow up . The above data suggests that extensive  
evaluation including bile microlith analysis , ERCP , SOM , EUS , empirical therapy  
for occult microlithiasis and follow up ( diagnosed chronic pancreatitis ) will detect  
a cause for RAP in almost all patients(93%). 
Genetic Studies : 
Genes that are implicated in pancreatitis are PRSS1,PRSS2 ,SPINK1 ,CFTR  
and Cathepsin B. Discovery of these genetic mutations have not only provided  
insight into the molecular mechanisms of pancreatitis but also presents the  
possibility of a powerful diagnostic tool.  
Several cases have beeen reported where patients with CFTR gene mutation  
without cystic fibrosis present with acute recurrent pancreatitis . These patients  
have compound heterozygosity in CFTR gene involving CFTR dele 2,3,(21 kb).  
These patients have congenital bilateral absence of vas deferens , normal sweat  
chloride concentration and no nasal polyps.(126) Though most studies on cationic  
trypsinogen and SPINK1 mutations have been in chronic pancreatitis , few studies  
have detected these mutations in acute pancreatitis . ( 3,6 ) 
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We analysed known mutations in PRSS1 gene (R122H,N29I) , PRSS2 gene  
(G191R),SPINK1 gene (N34S,P55S )  and polymorphisms in Exon 3 and 4 of  
Cathepsin B gene in a subset of 17 patients with RAP (Idiopathic :7 ; biliary :7 ;  
alcohol :2 ; papillary stenosis : 1 ) and 150 controls. None of the patients showed  
mutations in PRSS1 ,PRSS2 ,and SPINK1 genes. Analysis of Cathepsin B gene  
showed two polymorphisms in Exon 3 (C76G , T663C) and two in Exon 4 ( A790G,  
G834C) in patients with RAP and 18 polymorphisms in controls. C12T and A335T  
polymorphisms in Exon 3 were significantly more common in controls as compared  
to patients . C76 G heterozygosity was seen in 5/7 patients with Idiopathic RAP and  
3/7 patients with biliary RAP.  
 Our study suggests that gene mutations do not play a role in aetiopathogenesis of  
RAP. Definite conclusions are not possible due to small sample size studied .Large  
sample size and long term follow up are required to address the role of genetics in  
RAP and genetype phenotype correlations . 
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A suggested algorithm for the evaluation and management of RAP . 
.
Initial evaluation & management of  
Recurrent Acute Pancreatitis
History / Examination / 
LFT / lipids / Ca ++ / ANA; CA 19 : 9
US / CT abdomen
Episodic jaundice
Abnormal LFT
Cholelithiasis
Alcohol; Medication
Metabolic Tumour / CP Negative result
Eliminate / correct / treat
offending factor Treat appropriately
IdiopathicBiliary 
Pancreatitis
Cholecystectomy + IOC
ERCP / biliary sphinc
 
Step II. 
 
 
 
 
 
Step I: 
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CONCLUSIONS: 
1. Biliary disease (stone (20%); sludge / microlithiasis (28%) is the most common  
 cause of recurrent acute pancreatitis (RAP). 
2.  Determining etiology is important to assess the progressive nature of the disease .  
 The extent of evaluation impacts the frequency with which an etiology can be 
 found. 
 Bile for microliths and ERCP should therefore be part of evaluation of RAP as 
 these detect the etiology in 1/3rd  of patients. 
3.  Distribution of etiological factors was similar in East , South and North India. 
4.  After extensive evaluation including ERCP and testing  bile for microliths , a  
 cause for RAP could not be detected in 18% of patients. 
5.  Genetic mutations do not play a major role in the etiopathogenesis of RAP.  
 Further studies with larger sample size needs to be done. 
6.  Severe pancreatitis (14%) was predominantly seen in biliary and Idiopathic RAP. 
7.  Patients with biliary microlithiasis responded well to treatment with UDCA  and  
 biliary sphincterotomy. 
8.  Patients with pancreas divisum responded well to accessory papilla  
 sphincterotomy. 
9.  Some patients labeled as Idiopathic RAP may respond to empiric biliary  
 sphincterotomy as they may have occult biliary microlithiasis or sphincter of Oddi  
 dysfunction. 
10.  Patients (38%) labeled as Idiopathic RAP responded to empiric trial of  
 pancreatic enzymes. Large controlled trials are required to determine the role of  
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 pancreatic enzymes , antioxidants or octreotide in therapy of Idiopathic RAP. 
11.  Does Idiopathic RAP really exist ?  
 An etiology was obtained in 93% of patients after extensive evaluation , empiric  
 biliary sphincterotomy in Idiopathic RAP and development of chronic pancreatitis  
 on follow up.It is possible that on further follow up , the 7 % of patients may  
 progress to chronic pancreatitis. 
12.  Follow up of patients with idiopathic RAP is necessary as some may progress to  
 chronic pancreatitis. 
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i) that a research study on genetic mutations in recurrent acute pancreatitis is 
being conducted in the Department of G.I. Sciences, C.M.C.H., Vellore.   
ii) Information obtained from the study will be kept confidential.   
iii) A sample of 10ml of blood will be collected for this purpose. 
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Local -  Necrosis 
  Abscess 
  Pseudocyst 
  Ascites 
  Pleural effusion 
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Investigations 
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RADIOLOGY  
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Ultrasound  
CT Scan 
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ERCP 
GENETIC ANALYSIS : 
PRSS 1  R122H     N291 
PRSS 2 
SPINK 1 N34S        P55S 
Cathepsin B   
